Aarti Pharmalabs Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Small Cap

Revenue from operations increased 4.27% YoY to Rs 505.77 crore in Q4 FY24.

Profit before tax stood at Rs 95.75 crore , up 62.73% YoY.

Total expenses fell 3.49% to Rs 412.05 crore in Q4 FY24 as compared with Rs 426.96 posted in corresponding quarter last year. Cost of material stood at Rs 201.52 crore ( down 11.22%YoY), employee benefit expense was at Rs 37.40 crore ( up 12.55% YoY), finance cost stood 4.68 crore ( down 21.23% YoY) during the period under review.

Meanwhile, the board has declared a dividend of Rs 1 per equity share of face value of Rs 5 each for FY24.

Aarti Pharmalabs (APL) is an established, internationally recognised manufacturer of Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, New Chemical Entities (NCE), and xanthine derivatives situated in India.

Powered by Capital Market - Live News

Net profit of Aarti Pharmalabs rose 52.20% to Rs 65.25 crore in the quarter ended March 2024 as against Rs 42.87 crore during the previous quarter ended March 2023. Sales rose 4.27% to Rs 505.77 crore in the quarter ended March 2024 as against Rs 485.06 crore during the previous quarter ended March 2023.

For the full year,net profit rose 12.10% to Rs 216.90 crore in the year ended March 2024 as against Rs 193.49 crore during the previous year ended March 2023. Sales declined 4.76% to Rs 1852.61 crore in the year ended March 2024 as against Rs 1945.23 crore during the previous year ended March 2023.

Powered by Capital Market - Live News

Aarti Pharmalabs announced that the Board of Directors of the Company at its meeting held on 13 May 2024, has recommended a Final dividend of Rs.1 per share (i.e.20%), subject to the approval of the shareholders.

Powered by Capital Market - Live News

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 13 May 2024.

Powered by Capital Market - Live News